Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Pomerantz

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
JNCI Cancer Spectrum|January 26, 2022
DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American MenAnna Plym, Miklós Dióssy, Zoltan Szallasi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 4, 2011
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortalityMark M Pomerantz, Lillian Werner, Wanling Xie, et al.
European Urology Focus|July 21, 2017
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaGuillermo de Velasco, Kathryn P Gray, Lana Hamieh, et al.
International Journal of Radiation Oncology, Biology, Physics|January 13, 2026
Four-year Feasibility and Safety Results of a Phase I/II Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART) for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue MetastasesThomas P Howard, Tyler Walburn, Grant Benham, et al.
European Urology Oncology|April 5, 2025
Identifying Patients at Risk of Early Lethal Prostate Cancer by Integrating Family History, Polygenic Risk Score, Rare Variants in DNA Repair Genes, and Lifestyle FactorsZhizhu Zhang, Yiwen Zhang, Konrad H Stopsack, et al.
Brachytherapy|January 15, 2019
Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapyMartin T King, Paul L Nguyen, Ninjin Boldbaatar, et al.
European Urology|June 4, 2023
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven ProgramsSimon Linder, Tesa M Severson, Koen J C van der Mijn, et al.
Cancer|November 15, 2018
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancerRana R McKay, Lillian Werner, Susanna J Jacobus, et al.
Nature Communications|December 16, 2021
Androgen receptor and MYC equilibration centralizes on developmental super-enhancerHaiyang Guo, Yiming Wu, Mannan Nouri, et al.
BJU International|August 4, 2015
Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancerVinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
JNCI Cancer Spectrum|January 26, 2022
DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American MenAnna Plym, Miklós Dióssy, Zoltan Szallasi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 4, 2011
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortalityMark M Pomerantz, Lillian Werner, Wanling Xie, et al.
European Urology Focus|July 21, 2017
Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell CarcinomaGuillermo de Velasco, Kathryn P Gray, Lana Hamieh, et al.
International Journal of Radiation Oncology, Biology, Physics|January 13, 2026
Four-year Feasibility and Safety Results of a Phase I/II Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART) for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue MetastasesThomas P Howard, Tyler Walburn, Grant Benham, et al.
European Urology Oncology|April 5, 2025
Identifying Patients at Risk of Early Lethal Prostate Cancer by Integrating Family History, Polygenic Risk Score, Rare Variants in DNA Repair Genes, and Lifestyle FactorsZhizhu Zhang, Yiwen Zhang, Konrad H Stopsack, et al.
Brachytherapy|January 15, 2019
Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapyMartin T King, Paul L Nguyen, Ninjin Boldbaatar, et al.
European Urology|June 4, 2023
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven ProgramsSimon Linder, Tesa M Severson, Koen J C van der Mijn, et al.
Cancer|November 15, 2018
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancerRana R McKay, Lillian Werner, Susanna J Jacobus, et al.
Nature Communications|December 16, 2021
Androgen receptor and MYC equilibration centralizes on developmental super-enhancerHaiyang Guo, Yiming Wu, Mannan Nouri, et al.
BJU International|August 4, 2015
Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancerVinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, et al.
Pageof 7